Next Phase Newsletter

A large high-tech biological company focuses on rapid diagnostics in China – the company has gone public a few years ago. Apart from their headquarters, the firm has an international presence in Europe, Asia, and North America. The firm is open to different forms of partnership including license-in, joint venture, buyout, and equity investment for early-stage companies.

The firm has a strong interest in IVD sectors for innovative products addressing the unmet needs of healthcare providers.

The firm is open to global opportunities while preferring companies with a Chinese angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The firm is most interested in companies addressing North Asia, USA, Europe, and LATAM markets.

The firm will invest in therapeutics, medical devices, diagnostics, and digital health products. In therapeutics, the firm is currently most interested in cell and gene therapy, nucleic acid drugs, and all novel drug delivery products. The firm prefers to invest from early clinical stage (Phase I) and beyond. In medical devices, the firm is opportunistic and is open to all types of technologies. In diagnostics, the firm is primarily interested in IVD and diagnostics tools. The firm prefers to invest in products that have entered clinical testing, and is open to investing in both 510k and PMA devices. Lastly, in digital health, the firm is open to all types of technologies including those that leverage AI. In terms of indications, the firm is most interested in chronic disease therapy / care, neuron disorders, and oncology.

The firm is looking for competent, experienced, and reliable management teams when considering investment. The fund typically requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and venture builder based in the US invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in Infectious Disease technologies to partner and or invest with a current portfolio company. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An emerging venture fund is currently for their first fund and will invest from seed to early stage companies. The firm is interested in therapeutics, companion diagnostics, precision medicine, tools and manufacturing services. The firm generally invests $0.5-3 Million, and may participate as a fund of funds. The firm is focused on investments in Southern California, but can invest in companies nationwide.

Within therapeutics, the firm is interested in small molecules, biologics, RNA platforms, and cell and gene therapies. Outside of therapeutics, the firm is interested in companion diagnostics, precision medicine, life science tools, and novel manufacturing technologies. Indications of interest include oncology/IO, neurodegeneration, autoimmune disorders, cardiometabolic disorders and rare diseases.

The firm is willing to lead or co-invest, is an active investor, and will request board participation after an  investment in helping the entrepreneur and company improve their chances for seeking subsequent financings and building value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm has a unique model that takes early-stage pre-company technologies and supports them in company formation. The firm invests in early stage pre-proof-of-concept companies that may have a longer development timeline. The firm provides investment and – dependent on the company – advisory roles to support the company to its next step in development. The firm typically invests around $250,000 per company, and currently manages a low to mid-million dollar fund, though has access to a greater market flow. The firm currently holds a portfolio of 11-12 deals, and is seeking to add 6-7 deals in their pipeline. The firm leads investments for small early stage companies, and co-invests into deals that are greater than $500K. Even while making seed investments, the firm has the ability to syndicate deals and provide value with an advisory role. The firm focuses on companies based in North America (USA & Canada), and has previously made investments in Texas, Ohio, North and South Carolina, Florida, and Canada, among others.

The firm currently has 4 clusters of companies, each separated by the following categories: pet health; hospital channeled products (hospital supply); rehabilitation and mobility; and hospital acquired infection sterilization. While the firm is constantly finding technology in these four clusters, The firm is open to look at all life science technologies outside of these clusters, including biotech therapeutics (especially biologics and regenerative medicine), medical devices, and diagnostics. For medical devices, the firm looks mainly at 510K consumer products (included plastic surgery), and would only invest in PMA devices under the right circumstances as a minor player/syndicate. The firm typically invests in products in the pre-clinical, in-development stage when the product is still an idea.

The firm prefers an experienced team in the space, and will help handpick the management team around the deal. The firm typically takes a board seat after an investment, especially as the first ones in for seed stage companies. The firm will likely invest in products with no IP or prototype, and will put the firm’s network of engineers to support the product and work with the IP.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture fund headquartered in USA has 7 active portfolio companies and 1 exit. The fund’s typical check size is between $1-10M, with flexibility for follow-on investments. The fund focuses on US-based  companies and/or companies with US traction.

The firm is interested in tech-enabled services (addressing renal co-morbidities such as diabetes, cardiology, pulmonology, etc.), digital health (addressing patient or physician engagement), and renal IP (including diagnostics and non-invasive medical devices).

The firm is open to all types of management teams, but have a preference for entrepreneurial experience. The firm likes to typically see at least $1M in ARR for digital health and tech-enabled services companies. The firm prefers to join syndicates vs lead rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading venture capital firm dedicated to building next generation companies in the healthcare sector is focused on the cell and gene therapy and regenerative medicine sector and will consider opportunities encompassing therapeutics, diagnostics, and those harnessing data to revolutionize the sector. The firm partners with passionate teams that are backed by strong scientific platforms and will primarily invest in preclinical stage assets, contributing $1 – 2M initially. With operations in Japan and the United States, the fund takes a global approach to building value in their portfolio by linking these two important life science markets and leveraging the respective advantages of each ecosystem.

The firm invests exclusively in technologies relating to cell therapy and regenerative medicine, including precision medicine tools and discovery of new treatment modalities. The company can be in therapeutics, diagnostics or digital health. The firm’s primary areas of interest are oncology, autoimmune disorders, CNS, cardiovascular, renal and liver.

Most of the firm’s investments are in companies either located or looking to enter the Japanese market. The firm can lead or co-invest, and will generally take a board seat when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.